On 18 February 2022, Emotra AB (“Emotra” or “the Company”) disclosed that the Company had been... 220307 - Emotra - PR - Comments on Spotlight's decision to de-list
The Board of Directors and President of Emotra AB herewith present the year-end report for the financial year 2021. Emotra Year-end report for 2021 220222
On 18 February 2022, Emotra AB (“Emotra” or “the Company”) disclosed that the Company had been... 220221 - Emotra - PR - Plans for the period without official exchange trading
Today, on 18 February 2022, Emotra AB (“Emotra” or “the Company”) is disclosing that the... 220218 - Emotra - PR - Listing review at Spotlight halted
The data from our clinical multi-center study EUDOR-A have now been published. 220207-Emotra-PR-Publication-EUDOR_A
Today, the 6 of February, 2022, Emotra AB (“Emotra” or “the Company”) is announcing that... 220206 - Emotra - PR - Resignation of two board members
Today, on the 17th of January, 2022, Emotra AB (“Emotra” or “the Company”) is proud to... 220117 - Emotra - PR- Disclosure Notice and New Number of Shares
Today, 14 December, 2021, Emotra AB (“Emotra” or “the Company”) announced the results of the TO 2.... 211214 - Emotra - PR - Result of subscription warrants series TO 2
Following our acquisition of NeuraMetrix, Mangold Insight has released a new analysis of the company. 211207 - Emotra - PR - Mangold Insight publishes analysis of Emotra AB
The Board of Directors and the President of Emotra AB hereby present the interim report for the third quarter of 2021.... Interim report jan - sept 2021
